Bulevirtide

Bulevirtide

Chemical structure of Bulevirtide

Bulevirtide is an antiviral drug used in the treatment of chronic hepatitis D virus (HDV) infection. It is a first-in-class entry inhibitor that targets the sodium taurocholate co-transporting polypeptide (NTCP), which is a receptor for both hepatitis B and hepatitis D viruses on the surface of hepatocytes.

Mechanism of Action

Bulevirtide works by binding to the NTCP receptor on hepatocytes, thereby preventing the entry of HDV into the cells. This inhibition of viral entry reduces the replication of the virus and helps to control the infection. By blocking the entry of the virus, bulevirtide effectively reduces the viral load in patients with chronic hepatitis D.

Clinical Use

Bulevirtide is indicated for the treatment of chronic hepatitis D in patients with compensated liver disease. It is administered as a subcutaneous injection, typically once daily. The use of bulevirtide has been shown to improve liver function and reduce the levels of HDV RNA in the blood.

Side Effects

Common side effects of bulevirtide include injection site reactions, such as redness and swelling, as well as fatigue and headache. More serious side effects are rare but can include liver enzyme elevations, which require monitoring during treatment.

Development and Approval

Bulevirtide was developed as a novel therapeutic option for patients with chronic hepatitis D, a condition for which there were limited treatment options. It received conditional approval from the European Medicines Agency (EMA) in 2020, marking a significant advancement in the management of hepatitis D.

Related Pages

• Hepatitis D
• Hepatitis B
• Antiviral drug
• Liver disease